# OnCo record b-immunotherapy-response (bottleneck). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/bottlenecks/b-immunotherapy-response/>
  a schema:Thing ;
  onco:kind "bottleneck" ;
  schema:identifier "b-immunotherapy-response" ;
  schema:name "No one can predict who responds to immunotherapy"@en ;
  schema:description "Checkpoint drugs cure some patients and do nothing for most. We still cannot tell the two apart before treating."@en ;
  schema:url <https://onco.cc/bottlenecks/b-immunotherapy-response/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://doi.org/10.1001/jamanetworkopen.2019.2535>, <https://doi.org/10.1126/science.aar3593>, <https://doi.org/10.1016/j.jtho.2016.11.2228> ;
  onco:related <https://onco.cc/ideas/idea-cd8-pet-io/>, <https://onco.cc/ideas/idea-multimodal-foundation-model/>, <https://onco.cc/roadmaps/immunotherapy-roadmap/>, <https://onco.cc/ideas/idea-bio2-tcr-repertoire-early-readout/>, <https://onco.cc/ideas/idea-bio2-spatial-signature-cdx/>, <https://onco.cc/ideas/idea-bio2-ctdna-six-week-io-switch/>, <https://onco.cc/ideas/idea-bio2-io-biomarker-data-commons/>, <https://onco.cc/ideas/idea-bio2-til-reactivity-selection/>, <https://onco.cc/ideas/idea-bio2-antigen-presentation-triage/>, <https://onco.cc/ideas/idea-bio2-epigenetic-priming-cold-tumours/>, <https://onco.cc/ideas/idea-bio2-neoadjuvant-biomarker-engine/>, <https://onco.cc/ideas/idea-bio2-steroid-sparing-irae/> ;
  onco:cancers <https://onco.cc/cancers/nsclc/>, <https://onco.cc/cancers/melanoma/>, <https://onco.cc/cancers/head-and-neck/>, <https://onco.cc/cancers/urothelial/>, <https://onco.cc/cancers/gastric/>, <https://onco.cc/cancers/colorectal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/immuno-pet/>, <https://onco.cc/technologies/liquid-biopsy/>, <https://onco.cc/technologies/pathology-foundation-model/>, <https://onco.cc/technologies/digital-pathology-ai/>, <https://onco.cc/technologies/cgp/> ;
  onco:targets <https://onco.cc/targets/pd1/>, <https://onco.cc/targets/pdl1/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/nivolumab/>, <https://onco.cc/drugs/atezolizumab/>, <https://onco.cc/drugs/durvalumab/> ;
  onco:companies <https://onco.cc/companies/owkin/>, <https://onco.cc/companies/tempus/>, <https://onco.cc/companies/paige/>, <https://onco.cc/companies/foundation-medicine/> ;
  onco:terms <https://onco.cc/terms/tps/>, <https://onco.cc/terms/cps/>, <https://onco.cc/terms/tmb/>, <https://onco.cc/terms/msi/>, <https://onco.cc/terms/tils/>, <https://onco.cc/terms/cold-vs-hot/>, <https://onco.cc/terms/irae/>, <https://onco.cc/terms/ctdna/> ;
  onco:trials <https://onco.cc/trials/keynote-024-189/>, <https://onco.cc/trials/keynote-048/>, <https://onco.cc/trials/checkmate-067/>, <https://onco.cc/trials/keynote-177/> ;
  onco:keyPapers <https://onco.cc/key-papers/paper-haslam-jama-netw-open/>, <https://onco.cc/key-papers/paper-hirsch-j-thorac-oncol/>, <https://onco.cc/key-papers/paper-cristescu-science/> .